Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients

Launched by MAYO CLINIC · Jun 23, 2010

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the immune systems of both kidney transplant donors and recipients. Researchers want to take a closer look at the immune cells in bone marrow and lymph nodes to better understand how these cells behave in people who receive kidney transplants. This information could help improve the success of kidney transplants and make the process safer for patients.

If you or someone you know is between the ages of 65 and 74 and is either waiting for a kidney transplant or has already received one, you might be eligible to participate. Participants will need to provide written consent to join the study, and they can choose to leave the study at any time without affecting their medical care. However, certain health conditions, like specific blood count issues or recent serious illnesses, may prevent someone from being included. Participants can expect to undergo some tests related to their immune system, which are not part of regular medical care, but will help advance our understanding of kidney transplants.

Gender

ALL

Eligibility criteria

• • Inclusion criteria.
• • Pre or post renal transplant recipients.
• • Renal transplant donors.
• • Those who give voluntary written informed consent before performance of any study-related procedures, which are not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
• • Exclusion criteria.
• • Any patient currently receiving systemic anticoagulation therapy with heparin or coumadin.
• • Patient has a platelet count of \<30 x 10(9)/L within 14 days before enrollment.
• • Patient has an absolute neutrophil count of ANC\<1.0 x 10(9)/L within 14 days before enrollment.
• • Patient has received other investigational drugs within14 days before enrollment.
• • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• • Diagnosed or treated for malignancy within 5 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
• • Contraindication to kidney transplantation or donation-active infection, comorbid medical conditions, etc